DR 2313 structure
|
Common Name | DR 2313 | ||
---|---|---|---|---|
CAS Number | 284028-90-6 | Molecular Weight | 182.243 | |
Density | 1.5±0.1 g/cm3 | Boiling Point | 349.3±52.0 °C at 760 mmHg | |
Molecular Formula | C8H10N2OS | Melting Point | N/A | |
MSDS | USA | Flash Point | 165.0±30.7 °C |
Use of DR 2313DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo[1][2]. |
Name | 7,8-Dihydro-2-methyl-1H-thiopyrano[4,3-d]pyrimidin-4(5H)-one |
---|---|
Synonym | More Synonyms |
Description | DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo[1][2]. |
---|---|
Related Catalog | |
Target |
PARP-1:0.20 μM (IC50) PARP-2:0.24 μM (IC50) |
In Vitro | DR2313 (0.016-16.4 μM; 30 min) inhibits poly(ADP-ribosyl)ation reaction in nuclear extracts of rat brain, with a Ki of 0.23 μM[1]. DR2313 shows more powerful inhibition of the poly(ADP-ribosyl)ation in the nuclear extracts of the rat brain (IC50=0.20 μM) than 3AB (35.4 μM), PND (0.56 μM), DIQ (2.96 μM), and DPQ (0.96 μM)[1]. DR2313 (1-100 μM; 10 min) shows a weak inhibition of the mono(ADP-ribosyl)ation in a concentration-dependent manner (IC50=59 μM)[1]. DR2313 (0.1-30 μM; pretreated for 30 min) reduces hydrogen peroxide (500 μM; 4 h) or glutamate (1 mM; 30 min) induced excessive formation of poly(ADP-ribose) and cell death[1]. |
In Vivo | DR2313 (3-10 mg/kg i.v. bolus or infusion for 6 h) significantly reduces the cortical infarct volume in both permanent and transient focal ischemia models in rats[1]. Animal Model: Male Wistar rats (220-300 g) with permanent MCA occlusions (pMCAos) and transient MCA occlusions (tMCAos)[1] Dosage: 3, 10 mg/kg Administration: I.v. bolus and i.v. infusion for 6 h beginning 5 min before the onset of ischemia Result: Reduced the infarct volume in a dose-dependent manner in pMCAo and tMCAo model. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 349.3±52.0 °C at 760 mmHg |
Molecular Formula | C8H10N2OS |
Molecular Weight | 182.243 |
Flash Point | 165.0±30.7 °C |
Exact Mass | 182.051376 |
PSA | 71.05000 |
LogP | 0.66 |
Vapour Pressure | 0.0±0.8 mmHg at 25°C |
Index of Refraction | 1.714 |
Storage condition | 2~8°C |
Hazard Codes | Xn |
---|---|
RIDADR | NONH for all modes of transport |
HS Code | 2934999090 |
HS Code | 2934999090 |
---|---|
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
2-Methyl-1,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one |
3,5,7,8-Tetrahydro-2-methyl-4H-thiopyrano[4,3-d]pyrimidin-4-one |
2-methyl-3,5,7,8-tetrahydrothiopyrano(4,3-d)pyrimidine-4-one |
7,8-Dihydro-2-methyl-1H-thiopyrano[4,3-d]pyrimidin-4(5H)-one |
4H-Thiopyrano[4,3-d]pyrimidin-4-one, 1,5,7,8-tetrahydro-2-methyl- |
DR 2313 |
1,5,7,8-TETRAHYDRO-2-METHYL-4H-THIOPYRANO[4,3-D]PYRIMIDIN-4-ONE |
2-Methyl-1-sulfanyl-1H,4H,5H,7H,8H-pyrano[4,3-d]pyriMidin-4-one |
3,5,7,8-tetrahydro-2-methyl-4h-thiopyrano(4,3-d)pyrimidin-4-one |